Skip to main content

Advertisement

SpringerLink
Log in

Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study

  • Original article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

Advances in the treatment of MG have allowed most patients to effectively treat their disorder with oral medications. In parallel, non-adherence to medication treatment regimens is a worldwide health problem. Other chronic neurological disorders have already been associated with low adherence to treatment. However, the literature regarding adherence among patients with MG is definitely poor. The purpose of this study was to capture the prevalence and the associated factors of non-adherence to pharmacological treatment in patients with MG. We carried out a cross-sectional cohort study with 58 consecutive patients with MG from a university-affiliated referral hospital in São Paulo, Brazil. We registered clinical and sociodemographic data and patients were classified according to the MGFA classification. Clinical severity was assessed with myasthenia gravis composite (MGC) scale. Neuropsychiatric symptoms were evaluated with the Hospital Anxiety and Depression Scale (HADS) and quality of life with the 15-Item Quality Of Life Instrument for myasthenia gravis scale (MG-QOL15). Adherence to pharmacological treatment was evaluated using the 8-item Morisky Medication Adherence Scale (MMAS-8). There were 26 (44.8%) patients adherent to treatment. Low adherence was associated with poor educational attainment, longer time of disease and greater daily number of pills (p < 0.05). Patients with poor compliance to treatment presented worse quality of life and increased neuropsychiatric symptoms (p < 0.05). Adherence can be relatively challenging in patients with MG. Medical approach should recognize that therapeutic success in the treatment of MG goes through adherence to treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J (2012) Myasthenia gravis: a review. Autoimmune Dis 2012:874680. https://doi.org/10.1155/2012/874680

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023–1036. https://doi.org/10.1016/S1474-4422(15)00145-3

    Article  CAS  PubMed  Google Scholar 

  3. Richman DP, Agius MA (2003) Treatment of autoimmune myasthenia gravis. Neurology 61(12):1652–1661. https://doi.org/10.1212/01.WNL.0000098887.24618.A0

    Article  CAS  PubMed  Google Scholar 

  4. Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D (2015) Myasthenia gravis: association of British neurologists’ management guidelines. Pract Neurol 15(3):199–206. https://doi.org/10.1136/practneurol-2015-001126

    Article  PubMed  Google Scholar 

  5. Behin A, Le Panse R (2018) New pathways and therapeutic targets in autoimmune myasthenia gravis. J Neuromuscul Dis 5(3):265–277. https://doi.org/10.3233/JND-170294

    Article  PubMed  PubMed Central  Google Scholar 

  6. Osterberg L, Blaschke T (2005) Drug therapy: adherence to medication. N Engl J Med 353(5):487–497. https://doi.org/10.1056/NEJMra050100

    Article  CAS  PubMed  Google Scholar 

  7. Valldeoriola F, Coronell C, Pont C et al (2011) Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson’s disease: the ADHESON study. Eur J Neurol 18(7):980–987. https://doi.org/10.1111/j.1468-1331.2010.03320.x

    Article  CAS  PubMed  Google Scholar 

  8. de Ernst L, Harden CL, Pennel PB et al (2016) Medication adherence in women with epilepsy who are planning pregnancy. Epilepsia 57(12):2039–2044. https://doi.org/10.1111/epi.13586

    Article  PubMed  PubMed Central  Google Scholar 

  9. Idiáquez JF, González S, Lasso-Peñafiel J, Barnett C (2018) Adhesión al tratamiento farmacológico y descripción de sus factores asociados en pacientes con miastenia grave. Rev Neurol 66:15–20

    PubMed  Google Scholar 

  10. Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Ann Thorac Surg 70(1):327–334. https://doi.org/10.1212/WNL.55.1.16

    Article  PubMed  Google Scholar 

  11. Burns TM, Conaway M, Sanders DB (2010) The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 74(18):1434–1440. https://doi.org/10.1212/WNL.0b013e3181dc1b1e

    Article  PubMed  PubMed Central  Google Scholar 

  12. Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB (2011) The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve 43(1):14–18. https://doi.org/10.1002/mus.21883

    Article  PubMed  Google Scholar 

  13. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x

    Article  CAS  PubMed  Google Scholar 

  14. de Oliveira-Filho AD, Morisky DE, Neves SJF, Costa FA, De Lyra DP (2014) The 8-item Morisky Medication Adherence Scale: validation of a Brazilian–Portuguese version in hypertensive adults. Res Soc Adm Pharm 10(3):554–561. https://doi.org/10.1016/j.sapharm.2013.10.006

    Article  Google Scholar 

  15. Brown MT, Bussell JK (2011) Medication adherence: WHO cares? Mayo Clin Proc 86(4):304–314. https://doi.org/10.4065/mcp.2010.0575

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ferrari CMM, De Sousa RMC, Castro LHM (2013) Factors associated with treatment non-adherence in patients with epilepsy in Brazil. Seizure 22(5):384–389. https://doi.org/10.1016/j.seizure.2013.02.006

    Article  PubMed  Google Scholar 

  17. Santos-García D, Prieto-Formoso M, De La Fuente-Fernández R (2012) Levodopa dosage determines adherence to long-acting dopamine agonists in Parkinson’s disease. J Neurol Sci 318(1–2):90–93. https://doi.org/10.1016/j.jns.2012.03.018

    Article  CAS  PubMed  Google Scholar 

  18. Alkatheri A, Albekairy A (2013) Does the patients’ educational level and previous counseling affect their medication knowledge? Ann Thorac Med 8(2):105–108. https://doi.org/10.4103/1817-1737.109823

    Article  PubMed  PubMed Central  Google Scholar 

  19. Fleisher J, Bhatia R, Margus C, Pruitt A, Dahodwala N (2014) Health literacy and medication awareness in outpatient neurology. Neurol Clin Pract 4(1):71–81. https://doi.org/10.1212/01.CPJ.0000436211.73013.ab

    Article  PubMed  PubMed Central  Google Scholar 

  20. Nieuwlaat R, Wilczynski N, Navarro T et al (2014) Interventions for enhancing medication adherence. Cochrane Database Syst Ver 11:CD000011. https://doi.org/10.1002/14651858.cd000011.pub4

    Article  Google Scholar 

  21. Praska JL, Kripalani S, Seright AL, Jacobson TA (2005) Identifying and assisting low-literacy patients with medication use: a survey of community pharmacies. Ann Pharmacother 39(9):1441–1445. https://doi.org/10.1345/aph.1G094

    Article  PubMed  Google Scholar 

  22. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH (2007) Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120(8):713–719. https://doi.org/10.1016/j.amjmed.2006.08.033

    Article  PubMed  Google Scholar 

  23. Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23(8):1296–1310. https://doi.org/10.1016/S0149-2918(01)80109-0

    Article  CAS  PubMed  Google Scholar 

  24. Balu S, Simko RJ, Quimbo RM, Cziraky MJ (2009) Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin 25(11):2765–2775. https://doi.org/10.1185/03007990903297741

    Article  CAS  PubMed  Google Scholar 

  25. Chapman RH, Benner JS, Petrilla AA et al (2005) Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 165(10):1147–1152. https://doi.org/10.1001/archinte.165.10.1147

    Article  PubMed  Google Scholar 

  26. Varma A, Zis P (2019) Nocebo effect in myasthenia gravis: systematic review and meta-analysis of placebo-controlled clinical trials. Acta Neurol Belg 119(2):257–264. https://doi.org/10.1007/s13760-019-01143-1

    Article  PubMed  Google Scholar 

  27. Kulaksizoglu IB (2007) Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs 21(6):473–481. https://doi.org/10.2165/00023210-200721060-00004

    Article  CAS  PubMed  Google Scholar 

  28. Ybarra MI, Kummer A, Frota ERC, de Oliveira JT, Gomez RS, Teixeira AL (2011) Psychiatric disorders in myasthenia gravis. Arq Neuropsiquiatr 69(2A):176–179. https://doi.org/10.1590/s0004-282x2011000200006

    Article  PubMed  Google Scholar 

  29. Kronish IM, Rieckmann N, Halm EA et al (2006) Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med 21(11):1178–1183. https://doi.org/10.1111/j.1525-1497.2006.00586.x

    Article  PubMed  PubMed Central  Google Scholar 

  30. Scalzo P, Kummer A, Cardoso F, Teixeira AL (2009) Depressive symptoms and perception of quality of life in Parkinson’s disease. Arq Neuropsiquiatr 67(2A):203–208. https://doi.org/10.1590/s0004-282x2009000200006

    Article  PubMed  Google Scholar 

  31. Misra UK, Kalita J, Singh VK, Kumar S (2019) A study of comorbidities in myasthenia gravis. Acta Neurol Belg. https://doi.org/10.1007/s13760-019-01102-w

    Article  PubMed  PubMed Central  Google Scholar 

  32. DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med 160(14):2101–2107. https://doi.org/10.1001/archinte.160.14.2101

    Article  CAS  PubMed  Google Scholar 

  33. De Lapiscina EHM, Aguirre MEE, Blanco TA, Pascual IJ (2012) Myasthenia gravis: sleep quality, quality of life, and disease severity. Muscle Nerve 46(2):174–180. https://doi.org/10.1002/mus.23296

    Article  Google Scholar 

  34. Raggi A, Leonardi M, Antozzi C et al (2010) Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis. Neurol Sci 31(1):41–45. https://doi.org/10.1007/s10072-009-0167-y

    Article  PubMed  Google Scholar 

  35. Mourão A, Gomez R, Barbosa L et al (2016) Determinants of quality of life in Brazilian patients with myasthenia gravis. Clinics 71(7):370–374. https://doi.org/10.6061/clinics/2016(07)03

    Article  PubMed  PubMed Central  Google Scholar 

  36. Straka I, Minár M, Gažová A, Valkovič P, Kyselovič J (2018) Clinical aspects of adherence to pharmacotherapy in Parkinson disease: a PRISMA-compliant systematic review. Medicine (United States). 97(23):e10962. https://doi.org/10.1097/MD.0000000000010962

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Santa Casa de São Paulo School of Medical Sciences, Dr. Cesário Motta Júnior Street 112, São Paulo, 01221-020, Brazil

    Bruno Kusznir Vitturi, Ada Pellegrinelli & Berenice Cataldo Oliveira Valerio

Authors
  1. Bruno Kusznir Vitturi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ada Pellegrinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Berenice Cataldo Oliveira Valerio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruno Kusznir Vitturi.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vitturi, B.K., Pellegrinelli, A. & Valerio, B.C.O. Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study. Acta Neurol Belg 120, 83–89 (2020). https://doi.org/10.1007/s13760-019-01209-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-019-01209-0

Keywords

Search

Navigation